Data completeness
2/8 — Basic
SULFADIAZINE (sulfadiazine) by AbbVie. Approved for toxoplasmosis, burn wounds, hiv infections and 3 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sulfadiazine is an oral sulfonamide antibiotic tablet approved as an NDA by AbbVie, currently in pre-launch stage. It is indicated for toxoplasmosis, burn wounds, HIV infections, and various cancers including breast cancer, head and neck cancer, and radiation-induced dermatitis. The drug's mechanism of action and pharmacologic class are not specified in available data.
Pre-Launch
Pre-launch stage indicates small, focused team structure with emphasis on launch readiness, commercial planning, and regulatory compliance activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on SULFADIAZINE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.